By Hendra Lukman 
A groundbreaking advancement in stem cell transplantation is poised to transform treatment for patients with rare genetic disorders and potentially many other conditions requiring bone marrow replacement. Researchers at Stanford Medicine have successfully developed and tested a novel antibody-based therapy that prepares patients for life-saving stem cell transplants without the need for the highly toxic chemotherapy and radiation traditionally employed. This innovative approach, detailed in a phase 1 clinical trial, offers a significantly safer and more accessible pathway for individuals who previously faced prohibitive risks.
The initial focus of this pioneering research was on patients suffering from Fanconi anemia, a severe inherited disorder characterized by progressive bone marrow failure and a heightened susceptibility to infections and bleeding. For these vulnerable individuals, the conventional conditioning regimens – potent doses of chemotherapy and radiation designed to eliminate existing bone marrow stem cells – presented an unacceptable level of risk, often leading to severe side effects, secondary cancers, and even mortality. The Stanford team’s success in overcoming this hurdle not only offers renewed hope for Fanconi anemia patients but also signals a paradigm shift for a broader spectrum of diseases amenable to stem cell transplantation.
A New Era in Stem Cell Transplant Preparation
For decades, the standard protocol for stem cell transplantation has involved a brutal preparatory phase. Before introducing healthy donor stem cells, physicians must meticulously eradicate the patient’s own dysfunctional or diseased blood-forming stem cells. This process, known as myeloablation, is typically achieved through high-dose chemotherapy, often involving agents like busulfan, and/or total body irradiation. While effective in clearing the bone marrow, these treatments exact a heavy toll on the patient’s body, damaging healthy tissues, suppressing the immune system, and increasing the long-term risk of developing secondary malignancies.
The Stanford-led study introduced a fundamentally different strategy. Instead of relying on genotoxic agents, the researchers utilized an antibody, identified as briquilimab, designed to target a specific protein called CD117. This protein is abundantly expressed on the surface of hematopoietic stem cells, the very cells responsible for generating all blood and immune components. By binding to CD117, briquilimab acts as a targeted signal, prompting the elimination of these cells. Crucially, this antibody-mediated depletion occurs without the widespread collateral damage associated with traditional conditioning.
"We were able to treat these really fragile patients with a new, innovative regimen that allowed us to reduce the toxicity of the stem cell transplant protocol," stated Agnieszka Czechowicz, MD, PhD, assistant professor of pediatrics at Stanford Medicine and co-senior author of the study. "Specifically, we could eliminate the use of radiation and genotoxic chemotherapy called busulfan, with exceptional outcomes." The findings, published in the prestigious journal Nature Medicine, represent a significant leap forward in making stem cell transplantation a safer and more broadly applicable therapeutic option.
The Fanconi Anemia Challenge and a Patient’s Triumph
Fanconi anemia presents a particularly dire prognosis without intervention. The genetic defect impairs DNA repair mechanisms, leading to a critical shortage of red blood cells (causing anemia and fatigue), white blood cells (increasing susceptibility to infections), and platelets (leading to bleeding issues). By adolescence, approximately 80% of individuals with Fanconi anemia develop irreversible bone marrow failure, a condition that is often fatal.
The traditional solution, a stem cell transplant, offered a lifeline but came with its own set of grave risks. The harsh conditioning required to prepare for the transplant could exacerbate existing health problems or trigger new ones. "If they don’t get a transplant in time, Fanconi anemia patients’ bodies eventually will not make blood, so they die of bleeding or infections," explained Rajni Agarwal, MD, professor of pediatric stem cell transplantation and co-first author of the study. "The reason I am so excited about this trial is that it is a novel approach to help these patients, who are very vulnerable."
The phase 1 clinical trial enrolled three young children diagnosed with Fanconi anemia. These children, all under the age of 10, received a single intravenous dose of briquilimab approximately 12 days before their scheduled stem cell transplants. Following the antibody infusion, they received standard immune-suppressing medications but were spared the debilitating effects of busulfan or radiation. The donated stem cells were sourced from a parent and underwent specialized processing to remove immune cells that could trigger graft-versus-host disease (GVHD), a potentially life-threatening complication where the donor cells attack the recipient’s body.
Within two weeks of transplantation, the donated stem cells successfully engrafted in the patients’ bone marrow. Remarkably, none of the children experienced graft rejection. By one month post-transplant, the donor cells had begun to replace their own, a process that researchers initially aimed to achieve at a modest 1% level. The long-term follow-up, spanning two years, revealed an astonishing success rate: all three children achieved nearly 100% donor cell chimerism, meaning their bodies were now primarily populated by healthy, donor-derived blood-forming cells.
One of the first beneficiaries of this revolutionary therapy was Ryder Baker, an 11-year-old boy from Seguin, Texas. Before the transplant, Ryder’s life was significantly impacted by his Fanconi anemia. He experienced chronic fatigue, lacked stamina, and was frequently ill, which limited his ability to participate in activities that most children his age take for granted. His mother, Andrea Reiley, described his pre-transplant condition as a constant struggle, with even minor illnesses posing serious risks.
Ryder underwent his transplant at Lucile Packard Children’s Hospital Stanford in early 2022. The recovery, while still demanding, was marked by a profound absence of the severe toxicities typically associated with transplant conditioning. Today, Ryder is thriving. His mother reports a complete transformation: "He was so tired, he didn’t have stamina. It’s completely different now." Ryder has regained his energy, grown taller, gained weight, and is no longer debilitated by frequent infections. He recently completed fifth grade, actively participates in sports, and even received an "Up and Coming Player" award from his school soccer team, a testament to his restored vitality and well-being. Ryder’s mother expressed her profound relief and gratitude, noting the immense emotional burden lifted from her shoulders now that her son is free from the constant worry of severe illness. She also shared that Ryder takes pride in knowing his experience is paving the way for other children.
Addressing the Donor Match Dilemma
Beyond revolutionizing the conditioning regimen, the Stanford team also made significant strides in addressing another persistent challenge in stem cell transplantation: the scarcity of fully matched donors. Historically, a substantial percentage of patients – estimated at up to 40% – were unable to receive a transplant due to the lack of a compatible donor. This bottleneck often led to delayed treatment or the inability to proceed with transplantation altogether, particularly for individuals from diverse ethnic backgrounds where finding matches can be more difficult.
To mitigate this, the researchers implemented a novel approach to donor bone marrow modification. The donated marrow was processed to enrich for CD34+ cells, which are the crucial blood-forming stem cells, while simultaneously depleting immune cells known as alpha/beta T-cells. These T-cells are the primary culprits behind GVHD. By selectively removing them, the procedure enables the safe use of stem cells from half-matched donors, including biological parents. This innovation, pioneered by Alice Bertaina, MD, PhD, dramatically expands the pool of potential donors, making transplantation accessible to a much larger patient population.
"We are expanding the donors for stem cell transplantation in a major way, so every patient who needs a transplant can get one," Dr. Agarwal emphasized. This dual advancement – a gentler conditioning regimen and a broader donor pool – represents a comprehensive strategy to democratize access to this life-saving therapy.
The Legacy of Decades of Research
The success of this antibody therapy is not an overnight phenomenon but the culmination of over two decades of dedicated research at Stanford Medicine. The groundwork was laid by Irving Weissman, MD, a renowned stem cell biologist and former director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine. In 2004, Dr. Czechowicz began her studies on blood-forming stem cells as an undergraduate researcher in Dr. Weissman’s lab. Their early investigations in animal models demonstrated that blocking CD117 with antibodies could effectively eliminate stem cells without the need for radiation or chemotherapy.
This foundational work provided the scientific rationale for pursuing a clinical application. Through continued collaboration with other Stanford scientists, the team identified and refined a version of the antibody suitable for human use. This meticulous development process, spanning years of rigorous experimentation and refinement, ultimately led to the successful phase 1 clinical trial that has now yielded such promising results.
Broader Implications and Future Directions
The implications of this breakthrough extend far beyond Fanconi anemia. While stem cell transplants are most commonly associated with the treatment of blood cancers like leukemia and lymphoma, their application is expanding to a wider array of inherited blood disorders and immune deficiencies. As the safety and efficacy of the transplantation procedure improve, so too does its potential to benefit patients with conditions previously considered untreatable by this modality.
Researchers are optimistic that this antibody-based approach can be adapted for patients with other rare bone marrow failure syndromes, such as Diamond-Blackfan anemia. Furthermore, even in cancer patients, where chemotherapy and radiation are often essential for eradicating malignant cells, the antibody therapy might offer a less toxic conditioning option for elderly or frail patients who cannot tolerate the rigors of conventional treatments. "That population is often at a disadvantage," Dr. Agarwal noted. "It may provide us with a way to treat them with less intensity so it’s possible for them to get a transplant."
The Stanford team is actively pursuing these avenues. A phase 2 clinical trial is now underway, involving a larger cohort of children with Fanconi anemia to further validate the efficacy and safety of the antibody regimen. Concurrently, research is expanding to explore its applicability to other bone marrow failure disorders. The development of next-generation antibody-based treatments is also a priority, aiming to further refine outcomes and broaden the therapeutic landscape.
The impact on the lives of patients and their families is profound. For Dr. Agarwal, the opportunity to offer families a less toxic alternative is deeply rewarding. "When I counsel families, their eyes start to shine as they think, ‘OK, we can avoid the radiation and chemo toxicity’," she shared. This emotional resonance underscores the transformative potential of this scientific achievement.
Collaboration and Funding
This significant research endeavor was a collaborative effort involving numerous institutions and individuals. Key contributors include Agnieszka Czechowicz, MD, PhD; Rajni Agarwal, MD; Alice Bertaina, MD, PhD; and Matthew Porteus, MD, PhD, who served as co-senior author. The study also benefited from the expertise of researchers from the University of California, San Francisco; Kaiser Permanente Bernard J. Tyson School of Medicine; St. Jude Children’s Research Hospital; Memorial Sloan Kettering Cancer Center; and Jasper Therapeutics Inc.
The research received crucial financial support from anonymous donors, the California Institute for Regenerative Medicine, and the Fanconi Cancer Foundation. Jasper Therapeutics played a vital role by providing the briquilimab antibody, and the Stanford Clinical Trial Program was instrumental in facilitating the study’s implementation. This multidisciplinary and well-supported approach has been instrumental in bringing this life-changing therapy from the laboratory to the clinic. The success of this trial marks a pivotal moment, offering a beacon of hope and a tangible path toward safer, more effective stem cell transplantation for a generation of patients.
